Skip to content
Menu

Calidi Biotherapeutics, Inc. CLDI

Full chart Compare
Set alert

Price alert · CLDI

All alert types
0.48 USD -0.03 (-5.45%)

Regular-session close

0.47 -0.01 -2.58%

After hours · Nov 20, 5:29 PM ET

0.4654 Day range 0.52
0.4775 52-week range 24.64
YTD
-97.45%
1 year
-97.84%

5D -0.1725 (-26.54%)

0.50000.6000MonTueWedThuFri0.4775
Market cap
1.65M
EPS (ttm)
-38.71
Shares out
18.85M
Forward P/E
-1.57
YTD return
-97.45%
1-year return
-97.84%
50-day average
1.67
200-day average
2.22
Volume
47.78K
Avg volume
100.24K
Open
0.514
Previous close
0.505
Day's range
0.4654 – 0.52
52-week range
0.4775 – 24.64
Beta
0.57
Price target
6.25 (+1208.9%)

Key statistics

Enterprise value
24.96M
Free cash flow
-47.57M
Total cash
836.00K
Total debt
8.73M
Short % of float
5.77%

Fundamental scorecard

3 of 25 checks passed on CLDI’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CLDI Revenue — quarterly 0
CLDI Net income — quarterly -3.65M
CLDI EPS — quarterly -1.47

Upgrades / downgrades

CLDI analyst upgrades and downgrades
DateFirmActionFromTo
Jun 27, 2024Ladenburg Thalmanninit—Buy
May 15, 2024BairdmainOutperformOutperform
Mar 21, 2024BairdmainOutperformOutperform
Mar 21, 2024HC Wainwright & Co.mainBuyBuy
Nov 22, 2023HC Wainwright & Co.init—Buy
Oct 9, 2023Bairdinit—Outperform

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on CLDI — it syncs with the Stock Master app.

Insider holders

CLDI insider holders
InsiderRelationLatest transactionDateShares held
CAMAISA ALLANChief Executive OfficerSaleDec 16, 202466,712
FIRST LIGHT ACQUISITION GROUP LLCBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securitySep 11, 20230
LEFTWICH SCOTTDirectorStock Award(Grant)Jun 27, 2024560,873
SCHOENECK JAMES ADirectorStock Award(Grant)Jun 27, 20241,071,780
STEWART ALAN RDirectorStock Award(Grant)Jun 27, 2024154,087
VECCHIOLLA THOMAS ADirectorStock Award(Grant)Dec 20, 2023365,105

Institution ownership

CLDI institution ownership
Holder% heldSharesValueReported
Cable Car Capital LLC 0.40%82,937116.94KSep 29, 2024
CPR Investments Inc.0.27%56,00078.96KSep 29, 2024
Red Wave Investments, LLC0.23%46,46165.51KSep 29, 2024
Geode Capital Management, LLC0.19%39,61255.85KSep 29, 2024
Susquehanna International Group, LLP0.11%23,54433.20KSep 29, 2024
Delta Investment Management, LLC0.10%21,02329.64KSep 29, 2024

Fund ownership

CLDI fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.15%31,16643.94KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.05%10,00014.10KSep 29, 2024
Fidelity Total Market Index Fund0.05%10,16714.34KOct 30, 2024
Fidelity Series Total Market Index Fund0.04%7,44510.50KOct 30, 2024
Brinker Capital Destinations Tr-Destinations Multi Strategy Alt Fd0.03%7,0349.92KAug 30, 2024
Driehaus Event Driven Fund0.01%2,4363.43KSep 29, 2024